Regional EPO Deals: Large vs. Small Molecules
Executive Summary
Two recent deals in the EPO space by Astellas and Takeda show how Japanese pharma is competing at top level for product rights outside its domestic market, and illustrate the heady terms that next-generation EPO candidates command. They're also another sign that regional dealmaking is back.
You may also be interested in...
Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit
Vertex Pharmaceuticals deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950 underscore the significant potential for HCV protease inhibitors to alter the landscape of disease treatment and suggests pharmaceutical dealmakers will have to be ever more flexible to land biotech's best products.
Why EPO Matters
Dramatic events in the EPO market--roiled by patent fights, biosimilars, and next-generation products--are important not merely to the current EPO players. They affect nearly all large-molecule companies.
Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit
Vertex Pharmaceuticals deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950 underscore the significant potential for HCV protease inhibitors to alter the landscape of disease treatment and suggests pharmaceutical dealmakers will have to be ever more flexible to land biotech's best products.